---
date: "2021-04-10T00:00:00Z"
external_link: ""
image:
  focal_point: Smart
  preview_only: true
summary: Multicentre, open label, prospective, single arm study of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome
tags:
- Ongoing-trial
- SETS aHUS
title: SETS aHUS
url_code: ""
url_pdf: ""
url_slides: ""
url_video: ""
---

SETS aHUS is funded by a grant from the [NIHR's HTA Programme](https://www.nihr.ac.uk/explore-nihr/funding-programmes/health-technology-assessment.htm) to CI [Neil Sheerin](https://www.ncl.ac.uk/medical-sciences/people/profile/neilsheerin.html) and team.

It is a multicentre clinical trial, using an open label, prospective and single arm design, with non-blinded assessment of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome.

You can find out more [here](https://www.atypicalhus.co.uk/clinical-trials/sets-ahus-2/), from SETS aHUS's [award page](https://fundingawards.nihr.ac.uk/award/15/130/94), or from it's registration on [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT00838513).
